Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label AT1001 dose-level study in adult women with Fabry disease
2006-000181-36Phase 2Completed
- Sponsor
- Amicus Therapeutics
- Start
- Feb 2006
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of migalastat in Fabry disease (FD) (3 cohorts), sponsored by Amicus Therapeutics. Primary endpoint: Safety and tolerability. Started Feb 2006; status: completed.
02
Drugs
migalastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2006-000181-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000181-36.